These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 14747843)

  • 41. Toward Value-Based Pricing to Boost Cancer Research and Innovation.
    Ocana A; Amir E; Tannock IF
    Cancer Res; 2016 Jun; 76(11):3127-9. PubMed ID: 27197164
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Strategies for bringing drug delivery tools into discovery.
    Kwong E; Higgins J; Templeton AC
    Int J Pharm; 2011 Jun; 412(1-2):1-7. PubMed ID: 21421040
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Description of the French players from Avenir's investment program: the role of MabDesign].
    Groux N; Pontremoli R; Vuddamalay G; Richard G; Pons D
    Med Sci (Paris); 2019 Dec; 35(12):1198-1201. PubMed ID: 31903939
    [No Abstract]   [Full Text] [Related]  

  • 44. The pharmaceutical industry--prices and progress.
    Scherer FM
    N Engl J Med; 2004 Aug; 351(9):927-32. PubMed ID: 15329432
    [No Abstract]   [Full Text] [Related]  

  • 45. Mergers and innovation in the pharmaceutical industry.
    Comanor WS; Scherer FM
    J Health Econ; 2013 Jan; 32(1):106-13. PubMed ID: 23220457
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Escaping the pincer.
    Nat Rev Drug Discov; 2009 Dec; 8(12):915. PubMed ID: 19967796
    [No Abstract]   [Full Text] [Related]  

  • 47. Are the economics of pharmaceutical research and development changing?: productivity, patents and political pressures.
    Grabowski H
    Pharmacoeconomics; 2004; 22(2 Suppl 2):15-24. PubMed ID: 15660474
    [TBL] [Abstract][Full Text] [Related]  

  • 48. United States of America Department of Health and Human Services support for advancing influenza vaccine manufacturing in the developing world.
    Perdue ML; Bright RA
    Vaccine; 2011 Jul; 29 Suppl 1():A48-50. PubMed ID: 21684430
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The economics of follow-on drug research and development: trends in entry rates and the timing of development.
    DiMasi JA; Paquette C
    Pharmacoeconomics; 2004; 22(2 Suppl 2):1-14. PubMed ID: 15660473
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Innovation of novel antibiotics: an economic perspective.
    McKellar MR; Fendrick AM
    Clin Infect Dis; 2014 Oct; 59 Suppl 3():S104-7. PubMed ID: 25261536
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rising research and development costs for new drugs in a cost containment environment.
    DiMasi JA
    Pharmacoeconomics; 1992; 1(Suppl 1):13-20. PubMed ID: 10146926
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biotechnology in pharmaceuticals: the Japanese challenge.
    Dibner MD
    Science; 1985 Sep; 229(4719):1230-5. PubMed ID: 3898361
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
    Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
    J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [From a crisis to another...Pharmaceutical industry--economics].
    Scheen AJ
    Rev Med Liege; 2009 Jan; 64(1):3-5. PubMed ID: 19317093
    [No Abstract]   [Full Text] [Related]  

  • 55. Showcasing bioscience in Rhode Island.
    Spero D
    R I Med J (2013); 2013 Feb; 96(2):15. PubMed ID: 23641419
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Retail price regulation and innovation: reference pricing in the pharmaceutical industry.
    Bardey D; Bommier A; Jullien B
    J Health Econ; 2010 Mar; 29(2):303-16. PubMed ID: 20053474
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Aligning pharmaceutical innovation with medical need.
    Nathan C
    Nat Med; 2007 Mar; 13(3):304-8. PubMed ID: 17342145
    [No Abstract]   [Full Text] [Related]  

  • 58. Trends in risks associated with new drug development: success rates for investigational drugs.
    DiMasi JA; Feldman L; Seckler A; Wilson A
    Clin Pharmacol Ther; 2010 Mar; 87(3):272-7. PubMed ID: 20130567
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Advances in technology and business potential of new drug delivery systems.
    Momin M; Disouza J; Patravale V
    Drug Deliv Transl Res; 2016 Aug; 6(4):341. PubMed ID: 27365167
    [No Abstract]   [Full Text] [Related]  

  • 60. Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research.
    Cockburn IM; Henderson RM
    J Health Econ; 2001 Nov; 20(6):1033-57. PubMed ID: 11758047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.